European Psychiatry - Volume 41 - April 2017

542 / 916

S538 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S521–S582
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV0410
The impact of depression on the
human personality
M. Petrovi´c
Specialized Psychiatric Hospital “Gornja Toponica”, APM, Gornja
Toponica, Serbia
Depression is a common experience. We have all felt “depressed”
about a friend’s cold shoulder, misunderstandings in our marriage,
tussles with teenage children, sometimes we feel “down” for no
reason at all. However, depression can become an illness when:
– the mood state is severe;
– it lasts for 2 weeks or more and;
– it interferes with our ability to function at home or at work.
Signs of a depression includes:
– lowered self-esteem (or self-worth);
– change in sleep patterns, that is, insomnia or broken sleep;
– changes in appetite or weight;
– less ability to control emotions such as pessimism, anger, guilt,
irritability and anxiety;
– varying emotions throughout the day, for example, feeling worse
in the morning and better as the day progresses;
– reduces capacity to experience pleasure: you cannot enjoy what’s
happening now, nor look forward to anything with pleasure;
– hobbies and interests drop off;
– reduces pain tolerance: you are less able to tolerate aches and
pains and may have a host of new ailments;
– changes sex drive: absent or reduced;
– poor concentration and memory: some people are so impaired
that they think that they are becoming demented;
– reduces motivation; it does not seem worth the effort to do any-
thing, things seem meaningless;
– lowers energy levels.
At the Institute, we believe that personality and temperament
contribute to depression, particularly non-melancholic depression.
Certain personality types are more at risk of developing depression
than others.
Generally speaking, someone who is depressed would: have a low
mood, be pessimistic, have lowered self-esteem and feel hopeless
and helpless.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EV0411
Antidepressants and sexual
dysfunction: study with vortioxetina
O. Porta Olivares ∗, M. Juncal Ruiz ,
B. Fernández Abascal Puente Gómez Revuelta
M. Pérez Herrera arcia Ayala andera Rodríguez
N.I. Nu˜nez Morales Pardo de Santayana Jenaro
L. Sánchez Blanco
1 Hospital universitario Marqués de Valdecilla, General Psychiatry,
Santander, Spain
2 Hospital Universitario de Álava, General Psychiatry, Vitoria-Gasteiz,
Spain
∗ Corresponding author.
Introduction Antidepressant treatment, although it is effective to
improve the manifestations of major depression, may also induce
or exacerbate some symptoms of sexual dysfunction. Symptoms
such as decreased libido, anorgasmia, delayed ejaculation, erection
difficulty or dyspareunia, affect the quality of life of the subject
who suffers and the self-esteem, can lead to lack of adherence to
treatment and in accordingly, the relapse of depressive symptoms.
Serotonergic antidepressants are frequently associated with the
onset of sexual dysfunction in sexually active patients exceeding
70%. Clinicians underestimate the actual incidence of dysfunction
as the technical specifications of drugs show lower levels than 25%
and spontaneous reports of patients do not exceed 20-40%.
Aims Vortioxetina is a reuptake inhibitor of serotonin (5-HT) and
is also an agonist of the 5-HT1A partial agonist 5-HT1B and an
antagonist of 5-HT3, 5-HT1D and 5-HT7. Apparently, this molecule
at doses of between 5 and 15mg is safe and effective and does not
cause sexual dysfunction. It is a well-tolerated and safe, with low
incidence of sexual dysfunction.
Methods To evaluate the action we have evaluated sexual
dysfunction in patients with major depression before receiving
treatment vortioxetina (whether state or not previously treated
with other antidepressants) and at 2, 6 and 12months after starting
treatment with the drug. So we’ve used the SALSex scale (Scale for
measuring sexual dysfunction secondary to psychotropic drugs).
Results The results of this study are still being analyzed.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV0412
Cognitive symptoms in mayor
depression: A study with vortioxetina
O. Porta Olivares ∗, M. Juncal Ruiz ,
B. Fernández Abascal Puente , M. Gómez Revuelta ,
M. Pérez Herrera , G. Pardo de Santayana Jenaro ,
L. Sánchez Blanco , A.B. Pérez Santos ,
F. Arnaiz de las Revillas Almajano , R. Martín Gutiérrez ,
R. Landera Rodríguez
1 Hospital Universitario Marques De Valdecilla, General Psychiatry,
Santander, Spain
2 Hospital Universitario De Alava, General Psychiatry, Vitoria-gasteiz,
Spain
3 Hospital Universitario Marques De Valdecilla, General Medicine,
Santander, Spain
∗ Corresponding author.
Introduction The major depression is associated with decreased
cognitive functions in a range of areas, including attention, memory
and executive functions. The cognitive symptoms of depression can
have a profound effect on the ability of patients to keep out the tasks
of daily living, and are significant factors that affect the ability to
function both interpersonal and occupational level.
Aims Vortioxetina have a multimodal action acting on various
serotonin receptors in addition to inhibiting serotonin reuptake.
Vortioxetina, is a new therapeutic tool seems to have shown effi-
cacy in the treatment of cognitive symptoms of depression.
Methods To evaluate this action we have evaluated the cognitive
decline in patients with major depression before receiving treat-
ment vortioxetina (whether state or not previously treated with
other antidepressants) and at 2, 6 and 12 months after starting
treatment with the drug. For that, we’ve used the Verbal Hearing
Test King (RAVLT), which evaluates the auditory verbal short-term
memory, the learning rate, the retention of information, and the
differences between learning and recovery, and testing Digit sub-
stitution by symbols (DSST) that perform quick detection of brain
dysfunctions by a conventional task.
Results The results of this study are still under analysis.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.